
## Daniel Grossman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8723145/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immediate versus delayed insertion of the copper intrauterine device after medical abortion at 17–20 gestational weeks: a randomised controlled trial. BMJ Sexual and Reproductive Health, 2022, 48, 28-34.	0.9	3
2	Exploring Attitudes About the Legality of Self-Managed Abortion in the US: Results from a Nationally Representative Survey. Sexuality Research and Social Policy, 2022, 19, 574-587.	1.4	5
3	Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment. Contraception, 2022, 107, 36-41.	0.8	6
4	Barriers to abortion care and incidence of attempted self-managed abortion among individuals searching Google for abortion care: A national prospective study. Contraception, 2022, 106, 49-56.	0.8	18
5	A cross-sectional survey of U.S. abortion patients' interest in obtaining medication abortion over the counter. Contraception, 2022, 109, 25-31.	0.8	2
6	Making the case for advance provision of mifepristone and misoprostol for abortion in the United States. BMJ Sexual and Reproductive Health, 2022, 48, 238-242.	0.9	7
7	Time from first clinical contact to abortion in Texas and California. Contraception, 2022, 110, 76-80.	0.8	1
8	Accuracy of self-assessment of gestational duration among people seeking abortion. American Journal of Obstetrics and Gynecology, 2022, 226, 710.e1-710.e21.	0.7	19
9	Comprehension of an Over-the-Counter Drug Facts Label Prototype for a Mifepristone and Misoprostol Medication Abortion Product. Obstetrics and Gynecology, 2022, 139, 1111-1122.	1.2	4
10	The Impending Crisis of Access to Safe Abortion Care in the US. JAMA Internal Medicine, 2022, 182, 793.	2.6	26
11	Contraceptive use and access among deployed US servicewomen: findings from an online survey. BMJ Sexual and Reproductive Health, 2021, 47, 61-66.	0.9	6
12	Changes in Abortion in Texas Following an Executive Order Ban During the Coronavirus Pandemic. JAMA - Journal of the American Medical Association, 2021, 325, 691.	3.8	27
13	Introduction of telemedicine for medication abortion: Changes in service delivery patterns in two U.S. states. Contraception, 2021, 103, 151-156.	0.8	11
14	Medication Abortion With Pharmacist Dispensing of Mifepristone. Obstetrics and Gynecology, 2021, 137, 613-622.	1.2	22
15	Perspectives on self-managed abortion among providers in hospitals along the Texas–Mexico border. BMC Women's Health, 2021, 21, 132.	0.8	5
16	Two prophylactic pain management regimens for medical abortion â‰ <b>8</b> 3 days' gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception, 2021, 103, 163-170.	0.8	6
17	Could routine pregnancy self-testing facilitate earlier recognition of unintended pregnancy? A feasibility study among South African women. BMJ Sexual and Reproductive Health, 2021, , bmjsrh-2020-201017.	0.9	4
18	Pre-Abortion Informed Consent Through Telemedicine vs. in Person: Differences in Patient Demographics and Visit Satisfaction, Women's Health Issues, 2021, 31, 227-235.	0.9	8

#	Article	IF	CITATIONS
19	The Health Consequences of Restrictive Abortion Laws. JAMA Internal Medicine, 2021, 181, 713.	2.6	11
20	Improving Assessment of Demand for Postpartum Tubal Ligation among Publicly Insured Women in Texas. Contraception, 2021, 104, 518-523.	0.8	5
21	Obstetrician-gynecologist willingness to provide medication abortion with removal of the in-person dispensing requirement for mifepristone. Contraception, 2021, 104, 73-76.	0.8	9
22	Standardizing abortion research outcomes (STAR): Results from an international consensus development study. Contraception, 2021, 104, 484-491.	0.8	7
23	Disruptions to Abortion Care in Louisiana During Early Months of the COVID-19 Pandemic. American Journal of Public Health, 2021, 111, 1504-1512.	1.5	12
24	An observational study of patient experiences with a direct-to-patient telehealth abortion model in Australia. BMJ Sexual and Reproductive Health, 2021, , bmjsrh-2021-201259.	0.9	5
25	Border-state abortions increased for Texas residents after House Bill 2. Contraception, 2021, 104, 314-318.	0.8	13
26	Over-the-counter oral contraceptive use among women in Mexico: results from a national survey. BMJ Sexual and Reproductive Health, 2021, 47, 205-210.	0.9	3
27	A Randomized Study Evaluating the Effect of Evidence-Based Information on Clinician Attitudes About Moving Oral Contraceptives Over the Counter. Journal of Women's Health, 2021, 30, 1626-1636.	1.5	2
28	Breaking down barriers to birth control access: An assessment of online platforms prescribing birth control in the USA. Journal of Telemedicine and Telecare, 2020, 26, 322-331.	1.4	26
29	Characteristics of patients having telemedicine versus in-person informed consent visits before abortion in Utah. Contraception, 2020, 101, 56-61.	0.8	13
30	Texas women's decisions and experiences regarding self-managed abortion. BMC Women's Health, 2020, 20, 6.	0.8	28
31	Oral and IUD emergency contraception provision among a national sample of obstetrician–gynecologists. Contraception, 2020, 102, 406-408.	0.8	7
32	Pregnancy and Abortion: Experiences and Attitudes of Deployed U.S. Servicewomen. Military Medicine, 2020, 185, e1390-e1390.	0.4	3
33	Abortion Referral Practices among a National Sample of Obstetrician-Gynecologists. Women's Health Issues, 2020, 30, 446-452.	0.9	6
34	Modeling the Impacts of Price of an Over-the-Counter Progestin-Only Pill on Use and Unintended Pregnancy among U.S. Women. Women's Health Issues, 2020, 30, 153-160.	0.9	3
35	Telemedicine for Family Planning. Obstetrics and Gynecology Clinics of North America, 2020, 47, 287-316.	0.7	25
36	Mifepristone–misoprostol versus misoprostol-alone regimen for medication abortion at ≥24â€ <sup>-</sup> weeks' gestation. Contraception, 2020, 102, 99-103.	0.8	3

#	Article	IF	CITATIONS
37	Complications of Unsafe and Self-Managed Abortion. New England Journal of Medicine, 2020, 382, 1029-1040.	13.9	61
38	Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. Contraception, 2020, 101, 361-366.	0.8	113
39	Prevalence of Self-Managed Abortion Among Women of Reproductive Age in the United States. JAMA Network Open, 2020, 3, e2029245.	2.8	50
40	Expanding Access to Short-Acting Hormonal Contraceptive Methods in the United States. JAMA Internal Medicine, 2019, 179, 1209.	2.6	4
41	Miscarriage information available on the internet: a content analysis of leading consumer websites. Contraception: X, 2019, 1, 100010.	0.6	0
42	Experiences with pain of early medical abortion: qualitative results from Nepal, South Africa, and Vietnam. BMC Women's Health, 2019, 19, 118.	0.8	10
43	An analysis of delays among women accessing second-trimester abortion in the public sector in South Africa. Contraception, 2019, 100, 209-213.	0.8	11
44	Women's Experiences Using Telemedicine to Attend Abortion Information Visits in Utah: A Qualitative Study. Women's Health Issues, 2019, 29, 407-413.	0.9	22
45	Implementing best practices for the provision of long-acting reversible contraception: a survey of obstetrician-gynecologists. Contraception, 2019, 100, 123-127.	0.8	23
46	Challenging unintended pregnancy as an indicator of reproductive autonomy. Contraception, 2019, 100, 1-4.	0.8	98
47	Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee. Contraception, 2019, 99, 265-266.	0.8	23
48	Rebound of medication abortion in Texas following updated mifepristone label. Contraception, 2019, 99, 278-280.	0.8	9
49	Telemedicine for medication abortion. Contraception, 2019, 100, 351-353.	0.8	15
50	Change in Second-Trimester Abortion After Implementation of a Restrictive State Law. Obstetrics and Gynecology, 2019, 133, 771-779.	1.2	37
51	Induced Abortion Provision Among a National Sample of Obstetrician–Gynecologists. Obstetrics and Gynecology, 2019, 133, 477-483.	1.2	35
52	Support for and interest in alternative models of medication abortion provision among a national probability sample of U.S. women. Contraception, 2019, 99, 118-124.	0.8	29
53	Pharmacist Intentions to Prescribe Hormonal Contraception Following New Legislative Authority in California. Journal of Pharmacy Practice, 2019, 32, 54-61.	0.5	38
54	Providing Family Planning Services at Primary Care Organizations after the Exclusion of Planned Parenthood from Publicly Funded Programs in Texas: Early Qualitative Evidence. Health Services Research, 2018, 53, 2770-2786.	1.0	17

#	Article	IF	CITATIONS
55	Contraception after medication abortion in the United States: results from a cluster randomized trial. American Journal of Obstetrics and Gynecology, 2018, 218, 107.e1-107.e8.	0.7	9
56	Doing more for less: identifying opportunities to expand public sector access to safe abortion in South Africa through budget impact analysis. Contraception, 2018, 97, 167-176.	0.8	6
57	Abortion "Reversal―— Legislating without Evidence. New England Journal of Medicine, 2018, 379, 1491-1493.	13.9	19
58	Interest in Over-the-Counter Access to a Progestin-Only Pill among Women in the United States. Women's Health Issues, 2018, 28, 144-151.	0.9	26
59	Evaluating the capacity of California's publicly funded universities to provide medication abortion. Contraception, 2018, 98, 306-311.	0.8	7
60	A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study. PLoS ONE, 2018, 13, e0189195.	1.1	30
61	Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal. PLoS ONE, 2018, 13, e0191174.	1.1	28
62	Sixteen Years of Overregulation: Time to Unburden Mifeprex. New England Journal of Medicine, 2017, 376, 790-794.	13.9	85
63	The Use of Public Health Evidence in <i>Whole Woman's Health v Hellerstedt</i> . JAMA Internal Medicine, 2017, 177, 155.	2.6	7
64	Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion. Contraception, 2017, 95, 437-441.	0.8	39
65	Sexual and reproductive health under the Trump presidency: policy change threatens women in the USA and worldwide. Journal of Family Planning and Reproductive Health Care, 2017, 43, 89-91.	0.9	12
66	Over-the-Counter Access to Oral Contraceptives for Adolescents. Journal of Adolescent Health, 2017, 60, 634-640.	1.2	26
67	Does information about abortion safety affect Texas voters' opinions about restrictive laws? A randomized study. Contraception, 2017, 96, 381-387.	0.8	6
68	Safety of Medical Abortion Provided Through Telemedicine Compared With In Person. Obstetrics and Gynecology, 2017, 130, 778-782.	1.2	90
69	Telemedicine provision of medical abortion in Alaska: Through the provider's lens. Journal of Telemedicine and Telecare, 2017, 23, 680-685.	1.4	29
70	Integration of family planning services into HIV care clinics: Results one year after a cluster randomized controlled trial in Kenya. PLoS ONE, 2017, 12, e0172992.	1.1	35
71	Women's Knowledge of and Support for Abortion Restrictions in Texas: Findings from a Statewide Representative Survey. Perspectives on Sexual and Reproductive Health, 2016, 48, 189-197.	0.9	21
72	Perspectives among a Diverse Sample of Women on the Possibility of Obtaining Oral Contraceptives Over the Counter: AÂQualitative Study. Women's Health Issues, 2016, 26, 147-152.	0.9	11

#	Article	IF	CITATIONS
73	Experiences Accessing Abortion Care in Alabama among Women Traveling for Services. Women's Health Issues, 2016, 26, 298-304.	0.9	42
74	Women's experiences seeking abortion care shortly after the closure of clinics due to a restrictive law in Texas. Contraception, 2016, 93, 292-297.	0.8	85
75	Integrating family planning into HIV care in western Kenya: HIV care providers' perspectives and experiences one year following integration. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 209-213.	0.6	22
76	Reply to: "mifepristone by prescription: not quite a reality in Australia― Contraception, 2016, 94, 379.	0.8	0
77	Public funding for abortion where broadly legal. Contraception, 2016, 94, 453-460.	0.8	25
78	Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial. Reproductive Health, 2016, 13, 132.	1.2	6
79	Does Integrating Family Planning into HIV Services Improve Gender Equitable Attitudes? Results from a Cluster Randomized Trial in Nyanza, Kenya. AIDS and Behavior, 2016, 20, 1883-1892.	1.4	8
80	Clinical Outcomes and Women's Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa. PLoS ONE, 2016, 11, e0161843.	1.1	20
81	Women's Experience Obtaining Abortion Care in Texas after Implementation of Restrictive Abortion Laws: A Qualitative Study. PLoS ONE, 2016, 11, e0165048.	1.1	45
82	Unintended pregnancy among active-duty women in the United States military, 2011. Contraception, 2015, 92, 589-595.	0.8	31
83	Mifepristone by prescription: a dream in the United States but reality in Australia. Contraception, 2015, 92, 186-189.	0.8	44
84	Off-label indications for mifepristone in gynecology and obstetrics. Contraception, 2015, 92, 203-205.	0.8	0
85	Continuing pregnancy after mifepristone and "reversal―of first-trimester medical abortion: a systematic review. Contraception, 2015, 92, 206-211.	0.8	41
86	Incidence of Emergency Department Visits and Complications After Abortion. Obstetrics and Gynecology, 2015, 125, 175-183.	1.2	190
87	Delays and barriers to care in Colombia among women obtaining legal first―and secondâ€ŧrimester abortion. International Journal of Gynecology and Obstetrics, 2015, 131, 285-288.	1.0	24
88	Reaching women where they are: eliminating the initial in-person medical abortion visit. Contraception, 2015, 92, 190-193.	0.8	20
89	Over-the-Counter Access to Oral Contraceptives. Obstetrics and Gynecology Clinics of North America, 2015, 42, 619-629.	0.7	24
90	Women's Perspectives on Age Restrictions for Over-the-Counter Access to Oral Contraceptives. Journal of Adolescent Health, 2015, 56, 38-43.	1.2	4

#	Article	IF	CITATIONS
91	Self-induction of abortion among women accessing second-trimester abortion services in the public sector, Western Cape Province, South Africa: An exploratory study. South African Medical Journal, 2014, 104, 302.	0.2	21
92	Attitudes Toward Overâ€theâ€Counter Access To Oral Contraceptives Among a Sample Of Abortion Clients in the United States. Perspectives on Sexual and Reproductive Health, 2014, 46, 83-89.	0.9	17
93	Impact of family planning health talks by lay health workers on contraceptive knowledge and attitudes among HIV-infected patients in rural Kenya. Patient Education and Counseling, 2014, 94, 438-441.	1.0	10
94	A randomized trial of misoprostol versus laminaria before dilation and evacuation in South Africa. Contraception, 2014, 90, 234-241.	0.8	18
95	The public health threat of anti-abortion legislation. Contraception, 2014, 89, 73-74.	0.8	37
96	Mortality of induced abortion, other outpatient surgical procedures and common activities in the United States. Contraception, 2014, 90, 476-479.	0.8	31
97	Change in abortion services after implementation of a restrictive law in Texas. Contraception, 2014, 90, 496-501.	0.8	125
98	Unmet demand for highly effective postpartum contraception in Texas. Contraception, 2014, 90, 488-495.	0.8	77
99	Acceptability and clinical outcomes of first- and second-trimester surgical abortion by suction aspiration in Colombia. Contraception, 2014, 90, 242-248.	0.8	3
100	Women's and Providers' Experiences with Medical Abortion Provided Through Telemedicine: A Qualitative Study. Women's Health Issues, 2013, 23, e117-e122.	0.9	81
101	Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception, 2013, 88, 91-96.	0.8	52
102	Interest in over-the-counter access to oral contraceptives among women in the United States. Contraception, 2013, 88, 544-552.	0.8	62
103	Over-the-counter access to oral contraceptives as a reproductive healthcare strategy. Current Opinion in Obstetrics and Gynecology, 2013, 25, 500-505.	0.9	19
104	Integration of family planning services into HIV care and treatment in Kenya. Aids, 2013, 27, S77-S85.	1.0	72
105	Confronting the challenge of unsafe secondâ€ŧrimester abortion. International Journal of Gynecology and Obstetrics, 2011, 115, 77-79.	1.0	43
106	Continuation of Prescribed Compared With Over-the-Counter Oral Contraceptives. Obstetrics and Gynecology, 2011, 117, 551-557.	1.2	57
107	Surgical and medical second trimester abortion in South Africa: A cross-sectional study. BMC Health Services Research, 2011, 11, 224.	0.9	33
108	Effectiveness and Acceptability of Medical Abortion Provided Through Telemedicine. Obstetrics and Gynecology, 2011, 118, 296-303.	1.2	128

#	Article	IF	CITATIONS
109	Over-the-counter access to oral contraceptives. Expert Review of Obstetrics and Gynecology, 2011, 6, 501-508.	0.4	19
110	Clinic Versus Over-the-Counter Access to Oral Contraception: Choices Women Make Along the US–Mexico Border. American Journal of Public Health, 2010, 100, 1130-1136.	1.5	40
111	Bringing evidence to the debate on abortion coverage in health reform legislation: findings from a national survey in the United States. Contraception, 2010, 82, 129-130.	0.8	6
112	Self-induction of abortion among women in the United States. Reproductive Health Matters, 2010, 18, 136-146.	1.3	79
113	Complications after Second Trimester Surgical and Medical Abortion. Reproductive Health Matters, 2008, 16, 173-182.	1.3	99
114	Accuracy of Self-Screening for Contraindications to Combined Oral Contraceptive Use. Obstetrics and Gynecology, 2008, 112, 572-578.	1.2	80
115	Accuracy of a semi-quantitative urine pregnancy test compared to serum beta-hCG measurement: a possible screening tool for ongoing pregnancy after medication abortion. Contraception, 2007, 76, 101-104.	0.8	22
116	Women's Perspectives on Medical Abortion in Mexico, Colombia, Ecuador and Peru: A Qualitative Study. Reproductive Health Matters, 2005, 13, 75-83.	1.3	65